share_log

Clearmind Medicine | EFFECT: Others

Clearmind Medicine | EFFECT:其他

SEC announcement ·  03/25 06:03
Moomoo AI 已提取核心信息
Clearmind Medicine Inc., a company listed in the United States, has received a Notice of Effectiveness from the Securities and Exchange Commission (SEC) on March 22, 2024. The notice, identified by Accession Number 0001213900-24-024410 and Submission Type POS AM, signifies that the company's filing has been formally accepted by the SEC. The effectiveness of the filing, associated with File Number 333-276913, is a critical step in the regulatory process for Clearmind Medicine Inc.
Clearmind Medicine Inc., a company listed in the United States, has received a Notice of Effectiveness from the Securities and Exchange Commission (SEC) on March 22, 2024. The notice, identified by Accession Number 0001213900-24-024410 and Submission Type POS AM, signifies that the company's filing has been formally accepted by the SEC. The effectiveness of the filing, associated with File Number 333-276913, is a critical step in the regulatory process for Clearmind Medicine Inc.
在美国上市的公司Clearmind Medicine Inc. 已于2024年3月22日收到美国证券交易委员会(SEC)的生效通知。该通知以加入号0001213900-24-024410和提交类型为POS AM标识,表示该公司的申请已被美国证券交易委员会正式接受。该文件编号为333-276913,其有效性是Clearmind Medicine Inc.监管程序中的关键一步。
在美国上市的公司Clearmind Medicine Inc. 已于2024年3月22日收到美国证券交易委员会(SEC)的生效通知。该通知以加入号0001213900-24-024410和提交类型为POS AM标识,表示该公司的申请已被美国证券交易委员会正式接受。该文件编号为333-276913,其有效性是Clearmind Medicine Inc.监管程序中的关键一步。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息